Life science is a top priority for the Danish government and for Denmark as a nation. We will continue to improve framework conditions and exploring ways to future-proof the sector.
Featured Content
As Denmark prepares to assume the rotating presidency of the Council of the European Union on July 1st of 2025, attention is turning to what this small yet strategically positioned country will bring to the table. Under the slogan ‘A strong Europe in a changing world’, the Danish Ministry of Foreign Affairs highlights two overarching…
Roundup MEA: Gypto Pharma Partners with Dawa to Reinforce Egyptian Production; Hikma Invests USD 1 Billion in US-Based Operations
A selection of top stories coming out of the Middle East and Africa’s pharma sector: Egypt’s Gypto Pharma partners with US drugmaker Dawa to expand the local production of medicines; Jordan’s Hikma makes a USD 1 billion investment pledge for US manufacturing and R&D, and Riyadh-headquartered private equity firm Jadwa sets out to sell its…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract foreign biopharma investment. By promising international companies a better chance at winning government tenders, Sheinbaum hopes to increase domestic manufacturing, lower prices, and improve supply…
In Conversation
John ZHU – Founder, CEO, and Chairman, Duality Biotherapeutics
Drug assets are not like wine, they need to be in the right hands to realise their full potential.
Vanessa Vega Saenz – Director, Invest in Denmark
Investing in Danish life sciences means joining a robust and well-integrated ecosystem. The entire value chain, spanning from early-stage research to manufacturing and commercialisation, is accessible within the country.
Luc Henry – CEO, Limula
At Limula, we believe cell and gene therapy can transform the lives of many more patients than those who currently access it. We focus on solving one key bottleneck: scalable manufacturing.
Azad Bonni – SVP and Global Head of Neuroscience and Rare Diseases, pRED, Roche
We stand at the threshold of a new era in neuroscience, and the 2020s and 2030s will be marked by profound therapeutic breakthroughs that were once out of reach.
Sebastián Negrón Reichard – Secretary, Department of Economic Development & Commerce, Puerto Rico
We are at a unique juncture where Puerto Rico’s natural talents are aligned with broader global shifts
Daniel Palmacci – Head and President, Specialized Modalities, Lonza
In CGT, the line between innovator and CDMO is blurred. We invest significantly in internal R&D and process development capabilities, ensuring we remain at the forefront of technological advancement in a rapidly evolving marketplace.
Guangjin Pan – Managing Director, Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Science
We aim to ensure that scientific discoveries translate into real-world innovations that benefit patients and society.
Majid Al Fayyadh – CEO, King Faisal Specialist Hospital and Research Centre (KFSHRC)
The journey we are on is not just about growth and innovation; it is about creating meaningful change in the lives of patients, advancing medical research, and setting new standards of excellence
Op-Eds
InFigures
The top 10 pharma manufacturing companies in Italy, as collated by MonitorItalia and ranked by production value in 2022. Pfizer tops the list, followed by Novartis, and local player Chiesi. The remainder of the list is populated by familiar names from multinational pharma, although another Italian firm – Alfasigma – does sit in seventh place.…
The Top 10 Korean pharma companies ranked by 2023 sales, as compiled in the latest Citeline Scrip Asia 100. Hanmi leads the way with USD 1.14 billion in sales, a 10 percent increase on the previous year, followed by Daewoong and Boryung. Made with Visme Infographic Maker
The Japan Exchange Group (JPX) is a key platform for both established companies and emerging bio ventures in Japan. Recently, it has focused on fostering innovation and growth in sectors like biotechnology through its Growth Market segment. This market is specifically designed for early-stage companies, providing them with an avenue to raise capital while adhering…
Apart from a maturing regulatory environment and the expansion of healthcare coverage across the region, a number of other factors are contributing to the evolution of the MEA pharma market. Results from the second wave of a PhRMA-commisioned IQVIA market access study covering Saudi Arabia (KSA), UAE, Kuwait, Lebanon, Jordan, Egypt, Algeria, Morocco, Tunisia and…
